"PGE2, a major immunosuppressive factor in the tumor microenvironment, is believed to suppress tumor immunity through PGE2 receptor on immune cell and promote tumor progression. Preclinical data suggest that modulation of the PGE2 pathway through PGE2 receptor antagonists may complement immuno-oncology therapies, including anti-PD-1 antibody and anti-CTLA-4 antibody."
Yukio Tani, director of corporate communications at Ono Pharmaceutical Co. Ltd., which entered a license agreement with Bristol-Myers Squibb Co. for the development and commercialization of its compound, ONO-4578, a selective antagonist of EP4, a prostaglandin E2 (PGE2) receptor

"The LNM family of natural products is known to kill cancer cells by damaging DNA. In vitro, one can compare and contrast how effectively LNM and its analogues [damage] DNA. One can then study the efficacy of the most promising analogues merging from the in vitro study as anticancer drugs in tumor-bearing animal models in vivo."
Ben Shen, a professor with the Departments of Chemistry and Molecular Medicine at the Scripps Research Institute in Jupiter, Fla., and lead research of a group of scientists who have developed a new means of identifying promising new drug candidates from microbial natural products, using information stored in the genomes of the bacteria that produce them

"The market has made it clear they want the exchange to take action to broaden Hong Kong's capital markets access and enhance its competitiveness. By the second half of next year, we hope that we will see a significant number of innovative companies beginning to choose Hong Kong, making the Hong Kong market a relevant and even more competitive place."
Charles Li, Chief Executive, Hong Kong Exchanges and Clearing (HKEX)